

1 **The lectin-specific activity of *Toxoplasma gondii* microneme proteins 1
2 and 4 binds Toll-like receptor 2 and 4 N-glycans to regulate innate
3 immune priming**

4

5 Aline Sardinha-Silva^{1,2}, Flávia C. Mendonça-Natividade¹, Camila F. Pinzan¹, Carla D.
6 Lopes¹, Diego L. Costa², Damien Jacot³, Fabricio F. Fernandes¹, André L. V. Zorzetto-
7 Fernandes¹, Nicholas J. Gay⁴, Alan Sher², , Dragana Jankovic², Dominique Soldati-
8 Favre³, Michael E. Grigg^{2*}, Maria Cristina Roque-Barreira^{1*}

9

10 ¹ Department of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto
11 Medical School, University of São Paulo- USP (FMRP/USP), Ribeirão Preto, São
12 Paulo, 14049-900, Brazil

13 ² Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases,
14 National Institutes of Health, Bethesda, MD 20892, USA

15 ³ Department of Microbiology and Molecular Medicine, CMU, University of Geneva, 1
16 rue Michel-Servet, 1211 Geneva 4, Switzerland

17 ⁴ Department of Biochemistry, Cambridge University, 80 Tennis Court Road
18 Cambridge CB2 1GA, United Kingdom

19

20 *Corresponding authors:

21 Michael E. Grigg, Phone: +1 (301) 402-1609, e-mail: griggm@niaid.nih.gov; and Maria
22 Cristina Roque-Barreira, Phone: +55-16-3315-3062, e-mail: mcrbarre@fmrp.usp.br

23

24 **ABSTRACT**

25 Infection of host cells by *Toxoplasma gondii* is an active process, which is
26 regulated by secretion of microneme (MICs) and rhoptry proteins (ROPs and RONs) from
27 specialized organelles in the apical pole of the parasite. MIC1, MIC4 and MIC6 assemble
28 into an adhesin complex, secreted on the parasite surface and function to promote
29 infection competency. MIC1 and MIC4 are known to bind terminal sialic acid residues
30 and galactose residues, respectively and to induce IL-12 production from splenocytes.
31 Here we show that rMIC1- and rMIC4-stimulated dendritic cells and macrophages to
32 produce proinflammatory cytokines, and they do so by engaging TLR2 and TLR4. This
33 process depends on sugar recognition, since point mutations in the carbohydrate-
34 recognition domains (CRD) of rMIC1 and rMIC4 inhibit innate immune cells activation.
35 HEK cells transfected with TLR2 glycomutants were selectively unresponsive to MICs.
36 Following *in vitro* infection, parasites lacking MIC1 or MIC4, as well as expressing MIC
37 proteins with point mutations in their CRD, failed to induce wild-type (WT) levels of IL-
38 12 secretion by innate immune cells. However, only MIC1 was shown to impact systemic
39 levels of IL-12 and IFN- γ *in vivo*. Together, our data show that MIC1 and MIC4 interact
40 physically with TLR2 and TLR4 N-glycans to trigger IL-12 responses, and MIC1 is
41 playing a significant role *in vivo* by altering *T. gondii* infection competency and murine
42 pathogenesis.

43

44 **AUTHOR SUMMARY**

45 Toxoplasmosis is caused by the protozoan *Toxoplasma gondii*, belonging to the
46 Apicomplexa phylum. This phylum comprises important parasites able to infect a broad
47 diversity of animals, including humans. A particularity of *T. gondii* is its ability to
48 invade virtually any nucleated cell of all warm-blooded animals through an active
49 process, which depends on the secretion of adhesin proteins. These proteins are
50 discharged by specialized organelles localized in the parasite apical region, and termed
51 micronemes and rhoptries. We show in this study that two microneme proteins from *T.*
52 *gondii* utilize their adhesion activity to stimulate innate immunity. These microneme
53 proteins, denoted MIC1 and MIC4, recognize specific sugars on receptors expressed on
54 the surface of mammalian immune cells. This binding activates these innate immune
55 cells to secrete cytokines, which promotes efficient host defense mechanisms against the

56 parasite and regulate their pathogenesis. This activity promotes a chronic infection by
57 controlling parasite replication during acute infection.

58

59 INTRODUCTION

60 *Toxoplasma gondii* is a coccidian parasite belonging to the phylum Apicomplexa
61 and is the causative agent of toxoplasmosis. This protozoan parasite infects a variety of
62 vertebrate hosts, including humans with about one-third of the global population being
63 chronically infected [1]. Toxoplasmosis can be fatal in immunocompromised
64 individuals or when contracted congenitally [1], and is considered the second leading
65 cause of death from foodborne illnesses in the United States [2].

66 *T. gondii* invades host cells through an active process that relies on the parasite
67 actinomyosin system, concomitantly with the release of microneme proteins (MICs) and
68 rhoptry neck proteins (RONs) from specialized organelles in the apical pole of the
69 parasite [3]. These proteins are secreted by tachyzoites [4, 5] and form complexes
70 composed of soluble and transmembrane proteins. Some of the MICs act as adhesins,
71 interacting tightly with host cell-membrane glycoproteins and receptors, and are
72 involved in the formation of the moving junction [6]. This sequence of events ensures
73 tachyzoite gliding motility, migration through host cells, invasion and egress from
74 infected cells [4, 7]. Among the released proteins, MIC1, MIC4, and MIC6 form a
75 complex that, together with other *T. gondii* proteins, plays a role in the adhesion and
76 invasion of host cells [8, 9], contributing to the virulence of the parasite [10, 11].

77 Several studies have shown that host-cell invasion by apicomplexan parasites
78 such as *T. gondii* involves carbohydrate recognition [12-15]. Interestingly, MIC1 and
79 MIC4 have lectin domains [11, 16-18] that recognize oligosaccharides with sialic acid
80 and D-galactose in the terminal position, respectively. Importantly, the parasite's Lac⁺
81 subcomplex, consisting of MIC1 and MIC4, induces adherent spleen cells to release IL-
82 12 [17], a cytokine critical for the protective response of the host to *T. gondii* infection
83 [19]. In addition, immunization with this native subcomplex, or with recombinant MIC1
84 (rMIC1) and MIC4 (rMIC4), protects mice against experimental toxoplasmosis [20, 21].
85 The induction of IL-12 is typically due to detection of the pathogen by innate immunity
86 receptors, including members of the Toll-like receptor (TLR) family, whose stimulation
87 involves MyD88 activation and priming of Th1 responses, which protects the host
88 against *T. gondii* [19, 22]. It is also known that dysregulated expression of IL-12 and

89 IFN- γ during acute toxoplasmosis can drive a lethal immune response, in which mice
90 succumb to infection by severe immunopathology, the result of insufficient levels of IL-
91 10 and/or a collapse in the regulatory CD4+Foxp3+ T cell population [23, 24].

92 Interestingly, regarding the innate immune receptors associated with IL-12
93 response during several infections, the extracellular leucine-rich repeat domains of
94 TLR2 and TLR4 contain four and nine N-glycans, respectively [25]. Therefore, we
95 hypothesized that MIC1 and MIC4 bind TLR2 and TLR4 N-glycans on antigen-
96 presenting cells (APCs) and, through this interaction, trigger immune cell activation and
97 IL-12 production. To investigate this possibility, we assayed the ability of rMIC1 and
98 rMIC4 to bind and activate TLR2 and TLR4. Using several strategies, we demonstrated
99 that TLR2 and TLR4 are indeed critical targets for both MIC1 and MIC4. These
100 parasite and host cell structures establish lectin-carbohydrate interactions that contribute
101 to the induction of IL-12 production by innate immune cells, and we show here that the
102 MIC1 lectin promotes *T. gondii* infection competency and regulates parasite virulence
103 during *in vivo* infection.

104

105 **RESULTS**

106 **Lectin properties of recombinant MIC1 and MIC4 are consistent with those of the** 107 **native Lac⁺ subcomplex**

108 The native MIC1/4 subcomplex purified from soluble *T. gondii* antigens has
109 lectin properties, so we investigated whether their recombinant counterparts retained the
110 sugar-binding specificity. The glycoarray analysis revealed the interactions of: i) the
111 Lac⁺ subcomplex with glycans containing terminal α (2-3)-sialyl and β (1-4)- or β (1-3)-
112 galactose; ii), rMIC1 with α (2-3)-sialyl residues linked to β -galactosides; and iii) of
113 rMIC4 with oligosaccharides with terminal β (1-4)- or β (1-3)-galactose (Fig 1A). The
114 combined specificities of the individual recombinant proteins correspond to the dual
115 sugar specificity of the Lac⁺ fraction, demonstrating that the sugar-recognition
116 properties of the recombinant proteins are consistent with those of the native ones.

117 Based on the sugar recognition selectivity of rMIC1 and rMIC4, we tested two
118 oligosaccharides (α (2-3)-sialyllactose and lacto-N-biose) for their ability to inhibit the
119 interaction of the MICs with the glycoproteins fetuin and asialofetuin [26]. Sialyllactose
120 inhibited the binding of rMIC1 to fetuin, and lacto-N-biose inhibited the binding of
121 rMIC4 to asialofetuin (Fig 1B). To ratify the carbohydrate recognition activity of rMIC1

122 and rMIC4, we generated point mutations into the carbohydrate recognition domains
123 (CRDs) of the rMICs to abolish their lectin properties [11, 18, 27]. These mutated
124 forms, i.e. rMIC1-T126A/T220A and rMIC4-K469M, lost their capacity to bind to
125 fetuin and asialofetuin, respectively (Fig 1B), having absorbance as low as that in the
126 presence of the specific sugars. Thus, our results indicate that rMIC1 and rMIC4
127 maintained their lectin properties, and that the CRD function can be blocked either by
128 competition with specific sugars or by targeted mutations.

129 **rMIC1 and rMIC4 trigger the activation of DCs and macrophages**

130 We have previously demonstrated that the native Lac⁺ subcomplex stimulates
131 murine adherent spleen cells to produce proinflammatory cytokines [20]. We evaluated
132 whether recombinant MIC1 and MIC4 retained this property and exerted it on BMDCs
133 and BMDMs. BMDCs (Fig 2A-2D) and BMDMs (Fig 2E-2H) produced high levels of
134 the proinflammatory cytokines IL-12 (Fig 2A and 2E), TNF- α (Fig 2B and 2F), and IL-
135 6 (Fig 2C and 2G). This was not attributable to residual LPS contamination as the
136 recombinant protein assays were done in the presence of polymyxin B, and LPS levels
137 were less than 0.5ng/ml [see Materials and Methods section]. Although conventional
138 CD4⁺ Th1 cells are known to be the major producers of IL-10 during murine *T. gondii*
139 infection [28], we also found that rMIC1 and rMIC4 induced the production of this
140 cytokine by BMDCs (Fig 2D) and BMDMs (Fig 2H). We verified that the two
141 recombinant proteins induced the production of similar levels of IL-12, TNF- α , and IL-
142 6 by both BMDCs (Fig 2A-2C) and BMDMs (Fig 2E-2G). Both MICs induced the
143 production of similar levels of IL-10 in BMDCs (Fig 2D); however, BMDMs produced
144 significantly higher levels of IL-10 when stimulated with rMIC1 than when stimulated
145 with rMIC4 (Fig 2H). These cytokine levels were similar to those induced by the TLR4
146 agonist LPS. Thus, recombinant MIC1 and MIC4 induce a proinflammatory response in
147 innate immune cells, which is consistent with the results obtained for the native Lac⁺
148 subcomplex [20].

149 **The activation of macrophages by rMIC1 and rMIC4 depends on TLR2 and TLR4**

150 To investigate the mechanisms through which *T. gondii* MIC1 and MIC4
151 stimulate innate immune cells to produce cytokines, we assessed whether these MICs
152 can activate specific TLRs. To this end, BMDMs from WT, MyD88^{-/-}, TRIF^{-/-}, TLR2^{-/-},
153 TLR4^{-/-}, or TLR2/4 DKO mice, as well as HEK293T cells transfected with TLR2 or
154 TLR4, were cultured in the presence or absence of rMIC1 and rMIC4 for 48 hours. The

155 production of IL-12 by BMDMs (Fig 3A-3I) and IL-8 by HEK cells (Fig 3J and 3K)
156 were used as an indicator of cell activation. IL-12 production by BMDMs from MyD88^{-/-}, TRIF^{-/-}, TLR2^{-/-}, and TLR4^{-/-} mice was lower than that of BMDMs from WT mice
157 (Fig 3A-3D); no IL-12 was detected in cultures of TLR2/4 DKO mice cells stimulated
158 with either rMIC1 or rMIC4 (Fig 3E). These results show that TLR2 and TLR4 are both
159 relevant for the activation of macrophages induced by rMIC1 and rMIC4. The residual
160 cytokine production observed in macrophages from TLR2^{-/-} or MyD88^{-/-} mice may be
161 the result of activation of TLR4 (Fig 3A and 3C), and vice versa; e.g., the residual IL-12
162 levels produced by macrophages from TLR4^{-/-} mice may be the result of TLR2
163 activation. The finding that MICs fail to induce IL-12 production in DKO mice
164 BMDMs suggests that cell activation triggered by *T. gondii* MIC1 or MIC4 does not
165 require the participation of other innate immunity receptors beyond TLR2 and TLR4.
166 Nevertheless, because parasite components such as DNA or profilin engage TLR9,
167 TLR11, and TLR12 to produce IL-12 in macrophages [19, 22, 29], we investigated the
168 involvement of these receptors, as well as TLR3 and TLR5, in the response to rMIC1 or
169 rMIC4. BMDMs from TLR3^{-/-}, TLR5^{-/-}, TLR9^{-/-}, and TLR11/12 DKO mice stimulated
170 with rMIC1 or rMIC4 produced similar levels of IL-12 as cells from WT (Fig 3F-3I),
171 indicating that the activation triggered by rMIC1 or rMIC4 does not depend on these
172 receptors. Additionally, stimulation of HEK cells transfected with human TLR2 (Fig 3J)
173 or TLR4 (Fig 3K) with optimal concentrations of rMIC1 (Fig S1A and S1C) and rMIC4
174 (Fig S1B and S1D) induced IL-8 production at levels that were higher than those
175 detected in the absence of stimuli (medium), and similar to those induced by the
176 positive controls. Finally, by means of a pull-down experiment, we demonstrated a
177 physical interaction between rMIC1 and TLR2 or TLR4 and between rMIC4 and TLR2
178 or TLR4 (Fig 3L).

180 **Cell activation induced by rMIC1 and rMIC4 results from the interaction of their
181 CRDs with TLR2 and TLR4 N-glycans**

182 We hypothesized that in order to trigger cell activation, rMIC1 and rMIC4 CRDs
183 target oligosaccharides of the ectodomains of TLR2 (four N-linked glycans) [25] and
184 TLR4 (nine N-linked glycans) [30]. This hypothesis was tested by stimulating BMDCs
185 (Fig 4A) and BMDMs (Fig 4B) from WT mice with intact rMIC1 and rMIC4 or with
186 the mutated forms of these microneme proteins, namely rMIC1-T126A/T220A and
187 rMIC4-K469M, which lack carbohydrate binding activity [11, 18, 27]. IL-12 levels in

188 culture supernatants were lower upon stimulation with rMIC1-T126A/T220A or rMIC4-
189 K469M, showing that WT induction of cell activation requires intact rMIC1 and rMIC4
190 CRDs. The same microneme proteins were used to stimulate TLR2-transfected
191 HEK293T cells (Fig 4C), and similarly, lower IL-8 production was obtained in response
192 to mutated rMIC1 or rMIC4 compared to that seen in response to intact proteins. These
193 observations demonstrated that rMIC1 and rMIC4 CRDs are also necessary for inducing
194 HEK cell activation.

195 We used an additional strategy to examine the ability of rMIC1 and rMIC4 to
196 bind to TLR2 N-glycans. In this approach, HEK cells transfected with the fully N-
197 glycosylated TLR2 ectodomain or with the TLR2 glycomutants [25] were stimulated
198 with a control agonist (FSL-1) or with rMIC1 or rMIC4. HEK cells transfected with any
199 TLR2 form, except those expressing totally unglycosylated TLR2 (mutant $\Delta 1,2,3,4$),
200 were able to respond to FSL-1 (Fig 4D), a finding that is consistent with the previous
201 report that the $\Delta 1,2,3,4$ mutant is not secreted by HEK293T cells [25]. Cells transfected
202 with TLR2 lacking only the first or the third N-glycan (mutant $\Delta 1$; $\Delta 3$) responded to all
203 stimuli. The response to the rMIC1 stimulus was significantly reduced in cells
204 transfected with five different TLR2 mutants, lacking some combination of the second,
205 third, and fourth N-glycans (Fig 4D). Moreover, rMIC4 stimulated IL-8 production was
206 significantly reduced in cells transfected with the mutants lacking some combination of
207 the third and fourth N-glycans (Fig 4D).

208 These results indicate that *T. gondii* MIC1 and MIC4 use their CRDs to induce
209 TLR2- and TLR4-mediated cell activation. Among the TLR2 N-glycans, the rMIC1
210 CRD likely targets the second, third, and fourth glycan, whereas the rMIC4 CRD targets
211 only the third and fourth. Additionally, our findings suggested that TLR2 and TLR4
212 activation is required to enhance the production of IL-12 by APCs following rMIC
213 stimulation.

214 **The IL-12 production during *T. gondii* *in vitro* infection depends partially on MIC1
215 and MIC4 proteins and their ability to recognize carbohydrates on APCs surface.**

216 Because IL-12 production is induced by rMICS that engage TLR2 and TLR4 N-
217 glycans expressed on innate immune cells, we investigated whether such production is
218 impaired when APCs are infected with *T. gondii* lacking MIC1 and/or MIC4 proteins,
219 as well as complemented strains expressing mutant versions of these proteins that fail to
220 bind TLR2 or TLR4 carbohydrates. We generated $\Delta mic1$ and $\Delta mic4$ strains in an RH

221 strain expressing GFP and Luciferase using CRISPR/Cas9 to replace the endogenous
222 MIC gene with the drug-selectable marker HPT (HXGPRT – hypoxanthine-xanthine-
223 guanine phosphoribosyl transferase) (Fig 5A and 5B). We then complemented MIC
224 deficient parasites with mutated versions expressing an HA-tag, thus generating the
225 $\Delta\text{mic1}::\text{MIC1-T126A/T220A}^{\text{HA}}$ or $\Delta\text{mic4}::\text{MIC4-K469M}^{\text{HA}}$ strains (Fig 5A) that
226 expressed endogenous levels of MIC1 and MIC4 as confirmed by Western Blotting (Fig
227 5C).

228 IL-12 secretion by BMDCs and BMDMs infected with WT, Δmic1 ,
229 $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$, Δmic4 and $\Delta\text{mic4}::\text{K469M}$ parasites was assessed at 24
230 hours post infection. All mutant strains (Δmic1 , $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$, Δmic4
231 and $\Delta\text{mic4}::\text{K469M}$) induced lower IL-12 secretion by BMDCs (Fig 5D) and BMDMs
232 (Fig 5E) compared to that induced by WT parasites, indicating that engagement of
233 TLR2 and TLR4 cell surface receptors by the MIC lectin-specific activity led to an early
234 release of IL-12.

235 Using flow cytometry, we confirmed that parasites deficient in MIC1 or MIC4,
236 or mutated in their carbohydrate recognition domain resulted in lower intracellular IL-
237 12 production than WT infected BMDCs (Fig 5F-5H). Interestingly, the Toxo⁺ BMDCs
238 presented the same level of intracellular IL-12, independent of the *T. gondii* strain
239 infected (Fig 5F and 5H). Whereas the Toxo⁻ BMDCs produced less IL-12 when they
240 were infected with knockout or CRD-mutated *T. gondii* compared to WT-infected cells
241 (Fig 5G and 5H). Taken altogether, these results indicate that MIC1 and MIC4 induce
242 IL-12 production in innate immune cells during *in vitro* *T. gondii* infection. It is known
243 that other parasite factors act as IL-12 inducers, such as profilin, which is a TLR11 and
244 TLR12 agonist [29, 31], or GRA7 [32], GRA15 [33], and GRA24 [34], which directly
245 trigger intracellular signalling pathways in a TLR-independent manner, and these likely
246 account for the majority of IL-12 released after 24 hours of intracellular infection.

247

248 **MIC1, but not MIC4, contributes to the cytokine storm and acute death during *in***
249 ***vivo* murine infection with *T. gondii*.**

250 Given the importance of MIC1 and MIC4 as lectins that engage TLR2 and TLR4
251 N-glycans to induce increased levels of IL-12 release during *T. gondii* *in vitro* infection,
252 we investigated the biological relevance of these proteins during *in vivo* infection. Mice
253 were injected with 50 tachyzoites of RH WT, Δmic1 , $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$,

254 Δmic4 and $\Delta\text{mic4}::\text{MIC4-K469M}$ strains into the peritoneum of CD-1 outbred mice, a
255 lethal dose that causes acute mortality. The survival curve showed that parasites
256 deficient in MIC1 (Δmic1 group) or mutated to remove MIC1 lectin binding activity
257 ($\Delta\text{mic1}::\text{MIC1-T126A/T220A}$ group) were less virulent, resulting in a slight, but
258 significant ($p=0.0017$) increase in mouse survival (12 days post-infection) compared to
259 WT infected mice that all succumbed to infection by day 10 (Fig 6A). This was not the
260 result of a difference in parasite load, which was equivalent across all *T. gondii*-infected
261 mice at Day 5 (Fig 6D and 6I). Whereas, the absence of the MIC4 gene or MIC4 lectin
262 activity did not change the survival curve (Fig 6E) indicating that MIC4 is less relevant
263 than MIC1 during *in vivo* infection.

264 Acute mortality in CD-1 mice infected with Type I *T. gondii* is related to the
265 induction of a cytokine storm, mediated by high levels of IFN- γ production. Thus, we
266 measured systemic levels of IFN- γ and IL-12 in mice infected with WT, Δmic1 ,
267 $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$, Δmic4 and $\Delta\text{mic4}::\text{MIC4-K469M}$ strains. According to
268 Kugler et al. (2013), the peak of systemic IL-12p40 and IFN- γ during ME49-*T. gondii*
269 infection is between days 5-6 post-infection, therefore, we measured these cytokines in
270 the serum of CD-1-infected mice at day 5. Mice infected with Δmic1 or $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$ strains had 3-5 fold lower systemic levels of IL-12 (Fig 6B; $p=0.016$)
271 and IFN- γ (Fig 6C; $p\leq 0.0002$) than WT infected mice. In contrast, mice infected with
272 parasites lacking the MIC4 gene, or those expressing the mutant version of MIC4
273 showed no difference in IL-12 (Fig 6F) or IFN- γ (Fig 6G) compared to WT infected
274 mice. Hence, only MIC1 altered systemic levels of key cytokines induced during *T.*
275 *gondii* *in vivo* infection, and mice survived longer with lower systemic levels of
276 cytokines typically associated with acute mortality.

277 **MIC1 wild type complemented strain restores the cytokine storm and acute
278 mortality kinetics during *in vivo* infection with *T. gondii*.**

279 To formally show that MIC1 alters systemic levels of pro-inflammatory
280 cytokines associated with acute mortality, we complemented Δmic1 parasites at the
281 endogenous locus with a Type I allele of MIC1 expressing an HA tag (MIC1^{HA}).
282 Western blotting for either MIC1 or HA expression showed WT levels of MIC1
283 expression in the complemented parasites $\Delta\text{mic1}::\text{MIC1}^{\text{HA}}$ (Fig 7A). The complemented
284 strain restored WT virulence kinetics during *in vivo* infection and all mice died acutely,
285 in contrast to Δmic1 or $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$ parasites, that had a slight, but

287 significant delay in their acute mortality kinetics (Fig 7B; $p=0.0082$). Systemic levels of
288 IFN- γ (Fig 7C) and parasite load (Fig 7D and 7E) from mice infected with the
289 complemented strain were indistinguishable from WT. To better resolve the apparent
290 difference in acute mortality, parasites were injected into the right footpad to monitor
291 mouse weight loss and survival kinetics [35]. Mice infected locally in the footpad with
292 Δmic1 survived significantly longer, or did not die (Fig 7G; $p=0.0031$), and lost less
293 weight during acute infection (Fig 7F) than those infected with WT or $\Delta\text{mic1}:\text{MIC1}$
294 complemented parasites. Further, mice infected with $\Delta\text{mic1}:\text{MIC1-T126A/T220A}$
295 parasites that fail to bind TLR2 and TLR4 N-glycans *in vivo* also lost less weight and
296 survived significantly longer than WT or $\Delta\text{mic1}:\text{MIC1}$ complemented parasites (Fig 7F
297 and G). In conclusion, our results suggest that MIC1 operates in two distinct ways; as an
298 adhesin protein that promotes parasite infection competency, and as a lectin that
299 engages TLR N-glycans to induce a stronger proinflammatory immune response, one
300 that is unregulated and results in acute mortality upon RH infection of CD-1 mice.
301

302 DISCUSSION

303 In this study, we report a new function for MIC1 and MIC4, two *T. gondii*
304 microneme proteins involved in the host-parasite relationship. We show that rMIC1 and
305 rMIC4, by interacting directly with N-glycans of TLR2 and TLR4, trigger a
306 noncanonical carbohydrate recognition-dependent activation of innate immune cells.
307 This results in IL-12 secretion and the production of IFN- γ , a pivotal cytokine that
308 mediates parasite clearance and the development of a protective T cell response [19,
309 22], but in some cases, as seen during RH infection of CD-1 mice, promotes a
310 dysregulated cytokine storm and acute mortality, as seen during RH infection of CD-1
311 mice [36]. This MIC-TLR activation event explains, at least in part, the resistance
312 conferred by rMIC1 and rMIC4 administration against experimental toxoplasmosis [20,
313 21].

314 *T. gondii* tachyzoites express microneme proteins either on their surface or
315 secrete them in their soluble form. These proteins may form complexes, such as those of
316 MIC1, MIC4, and MIC6 (MIC1/4/6), in which MIC6 is a transmembrane protein that
317 anchors the two soluble molecules MIC1 and MIC4 [8]. Genetic disruption of each one
318 of these three genes does not interfere with parasite survival [8] nor its interaction with,
319 and attachment to, host cells [10]; however, MIC1 has been shown to play a role in

320 invasion and contributes to virulence in mice [10]. We previously isolated soluble
321 MIC1/4, a lactose-binding complex from soluble *T. gondii* antigens (STAg) [17], and its
322 lectin activity was confirmed by the ability of MIC1 to bind sialic acid [9] and MIC4 to
323 β -galactose [18]. We also reported that MIC1/4 stimulates adherent splenic murine cells
324 to produce IL-12 at levels as high as those induced by STAg [20]. Recently, it was also
325 demonstrated that MIC1, MIC4 and MIC6 are capable of inducing IFN- γ production
326 from memory T cells in mice chronically infected with *T. gondii* [37]. Our data herein
327 shows that MIC1/4 binds to and activates TLRs via a novel lectin-carbohydrate
328 interaction, rather than by its cognate receptor-ligand binding groove, establishing
329 precisely how the interactions of microneme protein(s) with defined glycosylated
330 receptor(s) expressed on the host cell surface are capable of altering innate priming of
331 the immune system.

332 To formally demonstrate the MIC1/MIC4 binding to glycosylated TLR cell
333 surface receptors we generated recombinant forms of MIC1 and MIC4, which retained
334 their specific sialic acid- and β -galactose-binding properties as indicated by the results
335 of their binding to fetuin and asialofetuin as well as the glycoarray assay. Both
336 recombinant MIC1 and MIC4 triggered the production of proinflammatory and anti-
337 inflammatory cytokines in DCs and macrophages via their specific recognition of TLR2
338 and TLR4 N-glycans, as well as by signaling through MyD88 and, partially, TRIF.
339 Importantly, our results establish how binding of rMIC1 and rMIC4 to specific N-
340 glycans present on TLR2 and TLR4 induces cell activation through this novel lectin-
341 carbohydrate interaction. The ligands for MIC1 and MIC4, α 2-3-sialyllactosamine and
342 β 1-3- or β 1-4-galactosamine, respectively, are terminal N-glycan residues found on a
343 wide-spectrum of mammalian cell surface-associated glycoconjugates. Thus, it is
344 possible that additional lectin-carbohydrate interactions may exist between MIC1/4 and
345 other cell surface receptors beyond TLR2 and TLR4. Such interactions likely evolved to
346 facilitate adhesion and promote the infection competency of a wide-variety of host cells
347 infected by *T. gondii*, further underscoring how these proteins exist as important
348 virulence factors [10] beyond immune priming. However, it is the immunostimulatory
349 capacity of rMIC1 and rMIC4 to target N-glycans on the ectodomains of TLR2 and
350 TLR4 that likely rationalizes how these microneme proteins function as a double-edged
351 sword during *T. gondii* infection. Mice infected by Type I strains die acutely due to a
352 failure to regulate the cytokine storm induced by high levels of IL-12 and IFN- γ [38],

353 39]. In this study, *T. gondii* Type I strains engineered to be deficient in MIC1 or
354 defective in binding TLR2/4 N-glycans lost less weight, survived significantly longer,
355 and produced less IL-12 and IFN- γ . Future studies that test whether the
356 immunostimulatory effect of MIC1/4 alters the pathogenesis and cyst burden of Type II
357 strains of *T. gondii* should be pursued to formally demonstrate that Type II parasites
358 rely on MIC1/4 induction of Th1-biased cytokines in order to limit tachyzoite
359 proliferation and induce a life-long persistent bradyzoite infection.

360 Several pathogens are known to synthesize lectins, which are most frequently
361 reported to interact with glycoconjugates on host cells to promote adherence, invasion,
362 and colonization of tissues [40-43]. Nonetheless, there are currently only a few
363 examples of lectins from pathogens that recognize sugar moieties present in TLRs and
364 induce IL-12 production by innate immune cells. Paracoccin, a GlcNAc-binding lectin
365 from the human pathogen *Paracoccidioides brasiliensis*, induces macrophage
366 polarization towards the M1 phenotype [44] and the production of inflammatory
367 cytokines through its interaction with TLR2 N-glycans [45]. Furthermore, the galactose-
368 adherence lectin from *Entamoeba histolytica* activates TLR2 and induces IL-12
369 production [46]. In addition, the mammalian soluble lectin SP-A, found in lung alveoli,
370 interacts with the TLR2 ectodomain [47]. The occurrence of cell activation and IL-12
371 production as a consequence of the recognition of TLR N-glycans has also been
372 demonstrated using plant lectins with different sugar-binding specificities [48, 49].

373 The binding of MIC1 and MIC4, as well as the lectins above, to TLR2 and
374 TLR4 may be associated with the position of the specific sugar residue present on the
375 receptor's N-glycan structure. Since the N-glycan structures of TLR2 and TLR4 are still
376 unknown, we assume that the targeted MIC1 and MIC4 residues, e.g. sialic acid α 2-3-
377 linked to galactose β 1-3- and β 1-4-galactosamines, are appropriately placed in the
378 receptors' oligosaccharides to allow the recognition phenomenon and trigger the
379 activation of innate immune responses.

380 Several *T. gondii* proteins have previously been shown to activate innate
381 immune cells in a TLR-dependent manner, but independent of sugar recognition. This is
382 the case for profilin (TgPRF), which is essential for the parasite's gliding motility based
383 on actin polymerization; it is recognized by TLR11 [29] and TLR12 [31, 50]. In
384 addition, *T. gondii*-derived glycosylphosphatidylinositol anchors activate TLR2 and
385 TLR4 [51], and parasite RNA and DNA are ligands for TLR7 and TLR9, respectively

386 [19, 22, 50]. The stimulation of all of these TLRs culminate in MyD88 activation which
387 results in IL-12 production [19, 22]. Several other *T. gondii* secreted effector proteins
388 regulate the production of proinflammatory cytokines such as IL-12, independent of
389 TLRs. For example, the dense granule protein 7 (GRA7) induces MyD88-dependent
390 NF- κ B activation, which facilitates IL-12, TNF- α , and IL-6 production [32]. MIC3 is
391 reported to induce TNF- α secretion and macrophage M1 polarization [52], whereas
392 GRA15 expressed by Type II strains activates NF- κ B, promoting the release of IL-12
393 [33], and GRA24 triggers the autophosphorylation of p38 MAP kinase and
394 proinflammatory cytokine and chemokine secretion [34]. In contrast, TgIST interferes
395 with IFN- γ induction by actively inhibiting STAT1-dependent proinflammatory gene
396 expression indicating that the parasite is capable of both activating as well as inhibiting
397 effector arms of the host immune response to impact its pathogenesis *in vivo* [53]. Thus,
398 multiple secretory effector proteins of *T. gondii*, including MIC1 and MIC4, appear to
399 work in tandem to ultimately promote protective immunity by either inducing or
400 dampening the production of proinflammatory cytokines, the timing of which is central
401 to controlling both the parasite's proliferation during the acute phase of infection and
402 the induction of an effective immune response capable of establishing a chronic
403 infection [19].

404 Our results regarding soluble MIC1 and MIC4 confirmed our hypothesis that
405 these two effector proteins induce the innate immune response against *T. gondii* through
406 TLR2- and TLR4-dependent pathways. This is consistent with previous studies that
407 highlight the importance of TLR signaling, as well as the MyD88 adapter molecule, as
408 essential for conferring resistance to *T. gondii* infection [29, 51, 54, 55]. In addition, we
409 show that both MIC1 and MIC4 on the parasite surface contribute to the secretion of IL-
410 12 by macrophages and DCs during *in vitro* infection, but only MIC1 plays a significant
411 role during *in vivo* infection, demonstrated by its ability to promote a dysregulated
412 induction of systemic levels of IFN- γ and a proinflammatory cytokine storm that leads
413 to acute mortality during murine infection.

414

415 METHODS

416 Ethics statement

417 All experiments were conducted in accordance to the Brazilian Federal Law
418 11,794/2008 establishing procedures for the scientific use of animals, and State Law

419 establishing the Animal Protection Code of the State of São Paulo. All efforts were
420 made to minimize suffering, and the animal experiments were approved by the Ethics
421 Committee on Animal Experimentation (*Comissão de Ética em Experimentação Animal*
422 - CETEA) of the Ribeirão Preto Medical School, University of São Paulo (protocol
423 number 065/2012), following the guidelines of the National Council for Control of
424 Animal Experimentation (*Conselho Nacional de Controle de Experimentação Animal* -
425 CONCEA).

426 **Lac⁺ fraction and recombinant MIC1 and MIC4**

427 The lactose-eluted (Lac⁺) fraction was obtained as previously reported [17, 21].
428 Briefly, the total soluble tachyzoite antigen (STAg) fraction was loaded into a lactose
429 column (Sigma-Aldrich, St. Louis, MO) and equilibrated with PBS containing 0.5 M
430 NaCl. The material adsorbed to the resin was eluted with 0.1 M lactose in equilibrating
431 buffer and dialyzed against ultrapure water. The obtained fraction was denoted as Lac⁺
432 and confirmed to contain MIC1 and MIC4. For the recombinant proteins, rMIC1 and
433 rMIC4 sequences were amplified from cDNA of the *T. gondii* strain ME49 with a 6-
434 histidine tag added on the N-terminal, cloned into pDEST17 vector (Gateway Cloning,
435 Thermo Fisher Scientific Inc., Grand Island, NY), and used to transform DH5 α *E. coli*
436 chemically competent cells for ampicillin expression selection, as described before [21].
437 The plasmids with rMIC1-T126A/T220A and rMIC4-K469M were synthesized by
438 GenScript (New Jersey, US) using a pET28a vector, and the MIC sequences carrying
439 the mutations were cloned between the *Nde*I and *Bam*H I sites. All plasmids extracted
440 from DH5 α *E. coli* were transformed in *E. coli* BL21-DE3 chemically competent cells
441 to produce recombinant proteins that were then purified from inclusion bodies and
442 refolded by gradient dialysis, as described previously for rMIC1 and rMIC4 wild type
443 forms [21]. Endotoxin concentrations were measured in all protein samples using the
444 Limulus Amebocyte Lysate Kit – QCL-1000 (Lonza, Basel, Switzerland). The rMIC1,
445 rMIC1-T126A/T220A, rMIC4 and rMIC4-K469M contained 7.2, 3.2, 3.5 and 1.1 EU
446 endotoxin/ μ g of protein, respectively. Endotoxin was removed by passing over two
447 polymyxin-B columns (Affi-Prep Polymyxin Resin; Bio-Rad, Hercules, CA).
448 Additionally, prior to all *in vitro* cell-stimulation assays, the proteins samples were
449 incubated with 50 μ g/mL of polymyxin B sulphate salt (Sigma-Aldrich, St. Louis, MO)
450 for 30 min at 37 °C to remove possible residual LPS.

451

452 **Glycan array**

453 The carbohydrate-binding profile of microneme proteins was determined by
454 Core H (Consortium for Functional Glycomics, Emory University, Atlanta, GA), using
455 a printed glycan microarray, as described previously [56]. Briefly, rMIC1-Fc, rMIC4-
456 Fc, and Lac⁺-Fc in binding buffer (1% BSA, 150 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂,
457 0.05% (w/v) Tween 20, and 20 mM Tris-HCl, pH 7.4) were applied onto a covalently
458 printed glycan array and incubated for 1 hour at 25 °C, followed by incubation with
459 Alexa Fluor 488-conjugate (Invitrogen, Thermo Fisher Scientific Inc., Grand Island,
460 NY). Slides were scanned, and the average signal intensity was calculated. The common
461 features of glycans with stronger binding are depicted in Fig. 1a. The average signal
462 intensity detected for all of the glycans was calculated and set as the baseline.

463 **Sugar-inhibition assay**

464 Ninety-six-well microplates were coated with 1 µg/well of fetuin or asialofetuin,
465 glycoproteins diluted in 50 µL of carbonate buffer (pH 9.6) per well, followed by
466 overnight incubation at 4 °C. Recombinant MIC1 or MIC4 proteins (both wild type
467 (WT) and mutated forms), previously incubated or not with their corresponding sugars,
468 i.e. α(2-3)-sialyllactose for MIC1 and lacto-N-biose for MIC4 (V-lab, Dextra, LA, UK),
469 were added into coated wells and incubated for 2 h at 25 °C. After washing with PBS,
470 *T. gondii*-infected mouse serum (1:50) was used as the source of the primary antibody.
471 The assay was then developed with anti-mouse peroxidase-conjugated secondary
472 antibody, and the absorbance was measured at 450 nm in a microplate-scanning
473 spectrophotometer (Power Wave-X; BioTek Instruments, Inc., Winooski, VT).

474 **Mice and parasites**

475 Female C57BL/6 (WT), MyD88^{-/-}, TRIF^{-/-}, TLR2^{-/-}, TLR3^{-/-}, TLR4^{-/-}, double
476 knockout (DKO) TLR2^{-/-}/TLR4^{-/-}, TLR5^{-/-}, and TLR9^{-/-} mice (all from the C57BL/6
477 background), 8 to 12 weeks of age, were acquired from the University of São Paulo -
478 Ribeirão Preto campus animal facility, Ribeirão Preto, São Paulo, Brazil, and housed in
479 the animal facility of the Department of Cell and Molecular Biology - Ribeirão Preto
480 Medical School, under specific pathogen-free conditions. The TLR11^{-/-}/TLR12^{-/-} DKO
481 mice were maintained at American Association of Laboratory Animal Care-accredited
482 animal facilities at NIAID/NIH. For the *in vivo* infections, female CD-1 outbred mice, 6
483 weeks of age were acquired from Charles River Laboratories, Germantown, MD, USA.

484 A clonal isolate of the *T. gondii* RH- Δ ku80/ Δ hpt strain was used to generate the
485 GFP/Luciferase strain, which was the recipient strain to generate the single-knockout
486 parasites. The GFP/Luc sequence was inserted into the UPRT locus of *Toxoplasma* by
487 double crossover homologous recombination using CRISPR/Cas-based genome editing
488 and selected for FUDR resistance to facilitate the targeted GFP/Luc gene cassette
489 knock-in. The MIC1 and MIC4 genes were replaced by the drug-selectable marker *hpt*
490 (*hxgprt* - hypoxanthine-xanthine-guanine phosphoribosyl transferase) flanked by LoxP
491 sites. For all gene deletions, 30 μ g of guide RNA was transfected along with 15 μ g of a
492 repair oligo. Parasites were transfected and selected as previously described [57, 58].
493 For the MIC gene complementation, the sequence was amplified from RH genomic
494 DNA with the addition of one copy of HA-tag sequence
495 (TACCCATACGATGTTCCAGATTACGCT) before the stop codon, and cloned into
496 pCR2.1-TOPO vector, followed by site-directed mutagenesis using the Q-5 kit (New
497 England Biolabs) in order to generate point mutations into MIC1 (MIC1-
498 T126A/T220A) and MIC4 (MIC4-K469M) sequences. For transfections, 30 μ g of guide
499 RNA was transfected along with 20 μ g of linearized pTOPO vector containing the MIC
500 mutated sequences.

501 Strains were maintained in human foreskin fibroblast (HFF) cells grown in
502 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-
503 inactivated foetal bovine serum (FBS), 0.25 mM gentamicin, 10 U/mL penicillin, and
504 10 μ g/mL streptomycin (Gibco, Thermo Fisher Scientific Inc., Grand Island, NY).

505 **Bone marrow-derived dendritic cells and macrophages**

506 Bone marrows of WT, MyD88 $^{-/-}$, TRIF $^{-/-}$, TLR2 $^{-/-}$, TLR3 $^{-/-}$, TLR4 $^{-/-}$, DKO
507 TLR2 $^{-/-}$ /TLR4 $^{-/-}$, TLR5 $^{-/-}$, TLR9 $^{-/-}$, and DKO TLR11 $^{-/-}$ /TLR12 $^{-/-}$ mice were harvested
508 from femurs and hind leg bones. Cells were washed with RPMI medium and
509 resuspended in RPMI medium with 10% FBS, 10 U/mL penicillin, and 10 μ g/mL
510 streptomycin (Gibco). For dendritic cell (DC) differentiation, we added 10 ng/mL of
511 recombinant murine GM-CSF (Prepotech, Rocky Hill, NJ), and 10 ng/mL murine
512 recombinant IL-4 (eBioscience, San Diego, CA); for macrophage differentiation, 30%
513 of L929 conditioned medium was added to RPMI medium with 10% FBS. The cells
514 were cultured in 100 \times 20 mm dish plates (Costar; Corning Inc., Corning, NY),
515 supplemented with respective conditioned media at days 3 and 6 for DCs, and at day 4
516 for macrophages. DCs were incubated for 8–9 days and macrophages for 7 days; the

517 cells were then harvested and plated into 24-well plates at 5×10^5 cells/well for protein
518 stimulations or *T. gondii* infections, followed by ELISA. Cell purity was analyzed by
519 flow cytometry. Eighty-five percent of differentiated dendritic cells were
520 CD11b⁺/CD11c⁺, while 94% of differentiated macrophages were CD11b⁺.

521 **HEK293T cells transfection**

522 Human embryonic kidney 293T (HEK293T) cells, originally acquired from
523 American Tissue Culture Collection (ATCC, Rockville, MD), were used as an
524 expression tool [59] for TLR2 and TLR4 [45, 60]. The cells grown in DMEM
525 supplemented with 10% FBS (Gibco), and were seeded at 3.5×10^5 cells/mL in 96-well
526 plates (3.5×10^4 cells/well) 24 h before transfection. Then, HEK293T cells were
527 transiently transfected (70-80% confluence) with human TLR2 plasmids as described
528 previously [25] or with CD14, CD36, MD-2 and TLR4 [61] using Lipofectamine 2000
529 (Invitrogen) with 60 ng of NF- κ B Luc, an NF- κ B reporter plasmid, and 0.5 ng of
530 *Renilla* luciferase plasmid, together with 60 ng of each gene of single and multiple
531 glycosylation mutants and of TLR2 WT genes [25]. After 24 h of transfection, the cells
532 were stimulated overnight with positive controls: P3C (Pam3CSK4; EMC
533 Microcollections, Tübingen, Germany), fibroblast stimulating ligand-1 (FSL-1; EMC
534 Microcollections), or LPS Ultrapure (standard LPS, *E. coli* 0111:B4; Sigma-Aldrich); or
535 with the negative control for cell stimulation (the medium). Cells transfected with
536 empty vectors, incubated either with the medium or with agonists (FSL-1 or P3C), were
537 also assayed; negative results were required for each system included in the study. IL-8
538 was detected in the culture supernatants. The absence of Mycoplasma contamination in
539 the cell culture was certified by indirect fluorescence staining as described previously
540 [62].

541 **Cytokine measurement**

542 The quantification of human IL-8 and mouse IL-12p40, IL-6, TNF- α , and IL-10
543 in the supernatant of the cultures was performed by ELISA, following the
544 manufacturer's instructions (OptEIA set; BD Biosciences, San Jose, CA). Human and
545 murine recombinant cytokines were used to generate standard curves and determine
546 cytokine concentrations. The absorbance was read at 450 nm using the Power Wave-X
547 spectrophotometer (BioTek Instruments).

548 **TLR2-FLAG and TLR4-FLAG plasmids**

549 The pcDNA4/TO-FLAG plasmid was kindly provided by Dr. Dario Simões
550 Zamboni. The pcDNA4-FLAG-TLR2 and pcDNA4-FLAG-TLR4 plasmids were
551 constructed as follows. RNA from a P388D1 cell line (ATCC, Rockville, MD) was
552 extracted and converted to cDNA with Maxima H Minus Reverse Transcriptase
553 (Thermo-Fisher Scientific, Waltham, MA USA) and oligo(dT). TLR2 and TLR4 were
554 amplified from total cDNA from murine macrophages by using Phusion High-Fidelity
555 DNA Polymerase and the phosphorylated primers TLR2_F:
556 ATGCTACGAGCTTTGGCTCTTCTGG, TLR2_R:
557 CTAGGACTTTATTGCAGTTCTCAGATTACCCAAAAC, TLR4_F:
558 TGCTTAGGATCCATGATGCCTCCCTGGCTCCTG and TLR4_R:
559 TGCTTAGCGGCCGCTCAGGTCCAAGTTGCCGTTCTTG. The fragments were
560 isolated from 1% agarose/Tris-acetate-ethylenediaminetetraacetic acid gel, purified
561 with GeneJET Gel Extraction Kit (Thermo-Fisher Scientific), and inserted into the
562 pcDNA4/TO-FLAG vector by using the restriction enzymes sites for NotI and XbaI
563 (Thermo-Fisher Scientific) for TLR2, and BamHI and NotI (Thermo-Fisher Scientific)
564 for TLR4. Ligation reactions were performed by using a 3:1 insert/vector ratio with T4
565 DNA Ligase (Thermo-Fisher Scientific) and transformed into chemically competent
566 *Escherichia coli* DH5 α cells. Proper transformants were isolated from LB agar
567 medium plates under ampicillin selection (100 μ g/mL) and analyzed by PCR,
568 restriction fragment analysis, and DNA sequencing. All reactions were performed
569 according to the manufacturer's instructions.

570 **Pull-down assay and Western Blot**

571 We used the lysate of HEK293T cells transfected (70-80% confluence) with
572 plasmids containing TLR2-FLAG or TLR4-FLAG. After 24 h of transfection, the HEK
573 cells were lysed with a non-denaturing lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl,
574 and 2 mM EDTA) supplemented with a protease inhibitor (Roche, Basel, Switzerland).
575 After 10 min of incubation on ice, the lysate was subjected to centrifugation (16,000 g,
576 at 4 °C for 5 min). The protein content in the supernatant was quantified by the BCA
577 method, aliquoted, and stored at -80 °C. For the pull-down assay, 100 μ g of the lysate
578 from TLR2-FLAG- or TLR4-FLAG-transfected HEK cells were incubated with 10 μ g
579 of TgMIC1 or TgMIC4 overnight at 4 °C. Since these proteins had a histidine tag, the
580 samples were purified on nickel-affinity resin (Ni Sepharose High Performance; GE

581 Healthcare, Little Chalfont, UK) after incubation for 30 min at 25 °C and centrifugation
582 of the fraction bound to nickel to pull down the TgMIC-His that physically interacted
583 with TLR-FLAG (16,000 g, 4 °C, 5 min). After washing with PBS, the samples were
584 resuspended in 100 µL of SDS loading dye with 5 µL of 2-mercaptoethanol, heated for
585 5 min at 95 °C, and 25 µL of total volume was run on 10% SDS-PAGE. After
586 transferring to a nitrocellulose membrane (Millipore, Billerica, MA), immunoblotting
587 was performed by following the manufacturer's protocol. First, the membrane was
588 incubated with anti-FLAG monoclonal antibodies (1:2,000) (Clone G10, ab45766,
589 Sigma-Aldrich) to detect the presence of TLR2 or TLR4. The same membrane was then
590 subjected to secondary probing and was developed with anti-TgMIC1 (IgY; 1:20,000)
591 or anti-TgMIC4 (IgY; 1:8,000) polyclonal antibodies and followed by incubation with
592 secondary polyclonal anti-chicken IgY-HRP (1:4,000) (A9046, Sigma-Aldrich) to
593 confirm the presence of TgMIC1 and TgMIC4.

594 ***In vitro infections***

595 Bone marrow-derived dendritic cells (BMDCs) and bone marrow-derived
596 macrophages (BMDMs) were infected with WT ($\Delta ku80/\Delta hpt$), $\Delta mic1$, $\Delta mic1::MIC1$ -
597 T126A/T220A, $\Delta mic4$ or $\Delta mic4::MIC4$ -K469M (Type I, RH background) strains
598 recovered from T25 flasks with HFF cell cultures. The T25 flasks were washed with
599 RPMI medium to completely remove parasites, and the collected material was
600 centrifuged for 5 min at 50 g to remove HFF cell debris. The resulting pellet was
601 discarded, and the supernatant containing the parasites was centrifuged for 10 min at
602 1,000 g and resuspended in RPMI medium for counting and concentration adjustments.
603 BMDCs and BMDMs were dispensed in 24-well plates at 5×10^5 cells/well (in RPMI
604 medium supplemented with 10% FBS), followed by infection with 3 parasites per cell
605 (multiplicity of infection, MOI 3). Then, the plate was centrifuged for 3 min at 200 g to
606 synchronize the contact between cells and parasites and incubated at 37 °C. The
607 supernatants were collected at 6, 12, 24, and 48 h after infection for quantification of
608 IL-12p40.

609 ***In vivo infections and Luciferase assay***

610 Six-week-old female CD-1 outbred mice were infected by intraperitoneal
611 injection with 50 tachyzoites of RH engineered strains diluted in 500 µL of phosphate-
612 buffered saline. The mice were weighed daily and survival was evaluated

613 Bioluminescent detection of firefly luciferase activity was performed at day 5
614 post-infection using an IVIS BLI system from Xenogen to monitor parasite burden.
615 Mice were injected with 3 milligrams (200 µl) of D-luciferin (PerkinElmer) substrate,
616 and after 5 minutes the mice were imaged for 300 seconds to detect the photons emitted.
617

618 **Statistical analysis**

619 The data were plotted and analysed using GraphPad Prism 7.0 software
620 (GraphPad, La Jolla, CA). Statistical significance of the obtained results was calculated
621 using analysis of variance (One-way ANOVA) followed by Bonferroni's multiple
622 comparisons test. Differences were considered significant when the *P* value was <0.05.
623

624 **ACKNOWLEDGEMENTS**

625 We are grateful to Dr. Tiago Wilson Patriarca Mineo (Universidade Federal de
626 Uberlândia - MG) for kindly provided us the wild type *Toxoplasma gondii* (RH); to Dr.
627 Larissa Dias Cunha and Dr. Dario Simões Zamboni (Universidade de São Paulo - SP)
628 for help with double knockout TLR2/TLR4 mice generation and for kindly provide the
629 pcDNA4/TO-FLAG plasmid; to Izaíra Tincani Brandão and Ana Paula Masson for
630 technical assistance with endotoxin measurements; to Patricia Vendrusculo, Sandra
631 Thomaz and Sara Hieny for all technical support essential for this study. We wish to
632 acknowledge the grants from Consortium for Functional Glycomics (#GM62116), for
633 doing the glycoarray assays; UK Medical Research Council (#G1000133 to N.J.G.), and
634 Wellcome Investigator Award (#WT100321/z/12/Z to N.J.G.). This work was
635 supported in part by the National Institute of Allergy and Infectious Diseases, National
636 Institutes of Health (A.S.S. and M.E.G.).
637

638 **REFERENCES**

- 639 1. Dubey JP. Toxoplasmosis of animals and humans. 2nd ed. Boca Raton, FL,
640 USA: CRC Press; 2009. 336 p.
- 641 2. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al.
642 Foodborne illness acquired in the United States--major pathogens. Emerging infectious
643 diseases. 2011;17(1):7-15. Epub 2011/01/05. doi: 10.3201/eid1701.P11101
644 10.3201/eid1701.091101p1. PubMed PMID: 21192848; PubMed Central PMCID:
645 PMC3375761.

646 3. Carruthers VB, Sibley LD. Sequential protein secretion from three distinct
647 organelles of *Toxoplasma gondii* accompanies invasion of human fibroblasts. European
648 journal of cell biology. 1997;73(2):114-23. Epub 1997/06/01. PubMed PMID: 9208224.

649 4. Carruthers VB, Giddings OK, Sibley LD. Secretion of micronemal proteins is
650 associated with toxoplasma invasion of host cells. Cellular microbiology.
651 1999;1(3):225-35. Epub 2001/02/24. PubMed PMID: 11207555.

652 5. Lovett JL, Sibley LD. Intracellular calcium stores in *Toxoplasma gondii* govern
653 invasion of host cells. Journal of cell science. 2003;116(Pt 14):3009-16. Epub
654 2003/06/05. doi: 10.1242/jcs.00596. PubMed PMID: 12783987.

655 6. Tomley FM, Soldati DS. Mix and match modules: structure and function of
656 microneme proteins in apicomplexan parasites. Trends in parasitology. 2001;17(2):81-8.
657 Epub 2001/03/03. PubMed PMID: 11228014.

658 7. Carruthers VB, Tomley FM. Microneme proteins in apicomplexans. Sub-cellular
659 biochemistry. 2008;47:33-45. Epub 2008/06/03. PubMed PMID: 18512339; PubMed
660 Central PMCID: PMC2847500.

661 8. Reiss M, Viebig N, Brecht S, Fourmaux MN, Soete M, Di Cristina M, et al.
662 Identification and characterization of an escorter for two secretory adhesins in
663 *Toxoplasma gondii*. The Journal of cell biology. 2001;152(3):563-78. Epub 2001/02/07.
664 PubMed PMID: 11157983; PubMed Central PMCID: PMC2196004.

665 9. Friedrich N, Santos JM, Liu Y, Palma AS, Leon E, Saouros S, et al. Members of
666 a novel protein family containing microneme adhesive repeat domains act as sialic acid-
667 binding lectins during host cell invasion by apicomplexan parasites. The Journal of
668 biological chemistry. 2010;285(3):2064-76. Epub 2009/11/11. doi:
669 10.1074/jbc.M109.060988. PubMed PMID: 19901027; PubMed Central PMCID:
670 PMC2804363.

671 10. Cerede O, Dubremetz JF, Soete M, Deslee D, Vial H, Bout D, et al. Synergistic
672 role of micronemal proteins in *Toxoplasma gondii* virulence. The Journal of
673 experimental medicine. 2005;201(3):453-63. Epub 2005/02/03. doi:
674 10.1084/jem.20041672. PubMed PMID: 15684324; PubMed Central PMCID:
675 PMC2213027.

676 11. Blumenschein TM, Friedrich N, Childs RA, Saouros S, Carpenter EP,
677 Campanero-Rhodes MA, et al. Atomic resolution insight into host cell recognition by
678 *Toxoplasma gondii*. The EMBO journal. 2007;26(11):2808-20. Epub 2007/05/12. doi:

679 10.1038/sj.emboj.7601704. PubMed PMID: 17491595; PubMed Central PMCID:
680 PMC1888667.

681 12. Monteiro VG, Soares CP, de Souza W. Host cell surface sialic acid residues are
682 involved on the process of penetration of *Toxoplasma gondii* into mammalian cells.
683 *FEMS microbiology letters*. 1998;164(2):323-7. Epub 1998/07/31. PubMed PMID:
684 9682481.

685 13. Ortega-Barria E, Boothroyd JC. A *Toxoplasma* lectin-like activity specific for
686 sulfated polysaccharides is involved in host cell infection. *The Journal of biological
687 chemistry*. 1999;274(3):1267-76. Epub 1999/01/09. PubMed PMID: 9880495.

688 14. Carruthers VB, Hakansson S, Giddings OK, Sibley LD. *Toxoplasma gondii* uses
689 sulfated proteoglycans for substrate and host cell attachment. *Infection and immunity*.
690 2000;68(7):4005-11. Epub 2000/06/17. PubMed PMID: 10858215; PubMed Central
691 PMCID: PMC101681.

692 15. Paing MM, Tolia NH. Multimeric assembly of host-pathogen adhesion
693 complexes involved in apicomplexan invasion. *PLoS pathogens*. 2014;10(6):e1004120.
694 Epub 2014/06/20. doi: 10.1371/journal.ppat.1004120. PubMed PMID: 24945143;
695 PubMed Central PMCID: PMC4055764.

696 16. Brecht S, Carruthers VB, Ferguson DJ, Giddings OK, Wang G, Jakle U, et al.
697 The *toxoplasma* micronemal protein MIC4 is an adhesin composed of six conserved
698 apple domains. *The Journal of biological chemistry*. 2001;276(6):4119-27. Epub
699 2000/10/29. doi: 10.1074/jbc.M008294200. PubMed PMID: 11053441.

700 17. Lourenco EV, Pereira SR, Faca VM, Coelho-Castelo AA, Mineo JR, Roque-
701 Barreira MC, et al. *Toxoplasma gondii* micronemal protein MIC1 is a lactose-binding
702 lectin. *Glycobiology*. 2001;11(7):541-7. Epub 2001/07/12. PubMed PMID: 11447133.

703 18. Marchant J, Cowper B, Liu Y, Lai L, Pinzan C, Marq JB, et al. Galactose
704 recognition by the apicomplexan parasite *Toxoplasma gondii*. *The Journal of biological
705 chemistry*. 2012;287(20):16720-33. Epub 2012/03/09. doi: 10.1074/jbc.M111.325928.
706 PubMed PMID: 22399295; PubMed Central PMCID: PMC3351351.

707 19. Yarovinsky F. Toll-like receptors and their role in host resistance to *Toxoplasma
708 gondii*. *Immunology letters*. 2008;119(1-2):17-21. Epub 2008/07/12. doi:
709 10.1016/j.imlet.2008.05.007. PubMed PMID: 18617274.

710 20. Lourenco EV, Bernardes ES, Silva NM, Mineo JR, Panunto-Castelo A, Roque-
711 Barreira MC. Immunization with MIC1 and MIC4 induces protective immunity against

712 Toxoplasma gondii. *Microbes and infection / Institut Pasteur*. 2006;8(5):1244-51. Epub
713 2006/04/18. doi: 10.1016/j.micinf.2005.11.013. PubMed PMID: 16616574.

714 21. Pinzan CF, Sardinha-Silva A, Almeida F, Lai L, Lopes CD, Lourenco EV, et al.
715 Vaccination with Recombinant Microneme Proteins Confers Protection against
716 Experimental Toxoplasmosis in Mice. *PLoS one*. 2015;10(11):e0143087. Epub
717 2015/11/18. doi: 10.1371/journal.pone.0143087. PubMed PMID: 26575028; PubMed
718 Central PMCID: PMC4648487.

719 22. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. *Nature reviews
720 Immunology*. 2014;14(2):109-21. Epub 2014/01/25. doi: 10.1038/nri3598. PubMed
721 PMID: 24457485.

722 23. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R,
723 et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma
724 gondii succumb to a lethal immune response dependent on CD4+ T cells and
725 accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. *J Immunol*.
726 1996;157(2):798-805. Epub 1996/07/15. PubMed PMID: 8752931.

727 24. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, Dos Santos L, et al.
728 Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during
729 lethal infection. *Immunity*. 2009;31(5):772-86. doi: 10.1016/j.jimmuni.2009.10.001.
730 PubMed PMID: 19896394; PubMed Central PMCID: PMC2814877.

731 25. Weber AN, Morse MA, Gay NJ. Four N-linked glycosylation sites in human
732 toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. *The Journal
733 of biological chemistry*. 2004;279(33):34589-94. Epub 2004/06/03. doi:
734 10.1074/jbc.M403830200. PubMed PMID: 15173186.

735 26. Santos A, Carvalho FC, Roque-Barreira MC, Zorzetto-Fernandes AL, Gimenez-
736 Romero D, Monzo I, et al. Evidence for Conformational Mechanism on the Binding of
737 TgMIC4 with beta-Galactose-Containing Carbohydrate Ligand. *Langmuir : the ACS
738 journal of surfaces and colloids*. 2015;31(44):12111-9. Epub 2015/10/22. doi:
739 10.1021/acs.langmuir.5b03141. PubMed PMID: 26488670.

740 27. Hager KM, Carruthers VB. MARveling at parasite invasion. *Trends in
741 parasitology*. 2008;24(2):51-4. Epub 2008/01/22. doi: 10.1016/j.pt.2007.10.008.
742 PubMed PMID: 18203663; PubMed Central PMCID: PMC2662992.

743 28. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, et
744 al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective

745 regulatory IL-10 during intracellular protozoan infection. *The Journal of experimental*
746 *medicine*. 2007;204(2):273-83. Epub 2007/02/07. doi: 10.1084/jem.20062175. PubMed
747 PMID: 17283209; PubMed Central PMCID: PMC2118735.

748 29. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS,
749 et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. *Science*.
750 2005;308(5728):1626-9. Epub 2005/04/30. doi: 10.1126/science.1109893. PubMed
751 PMID: 15860593.

752 30. da Silva Correia J, Ulevitch RJ. MD-2 and TLR4 N-linked glycosylations are
753 important for a functional lipopolysaccharide receptor. *The Journal of biological*
754 *chemistry*. 2002;277(3):1845-54. Epub 2001/11/14. doi: 10.1074/jbc.M109910200.
755 PubMed PMID: 11706042.

756 31. Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, et al.
757 Recognition of profilin by Toll-like receptor 12 is critical for host resistance to
758 *Toxoplasma gondii*. *Immunity*. 2013;38(1):119-30. Epub 2012/12/19. doi:
759 10.1016/j.jimmuni.2012.09.016. PubMed PMID: 23246311; PubMed Central PMCID:
760 PMC3601573.

761 32. Yang CS, Yuk JM, Lee YH, Jo EK. *Toxoplasma gondii* GRA7-Induced TRAF6
762 Activation Contributes to Host Protective Immunity. *Infection and immunity*.
763 2015;84(1):339-50. Epub 2015/11/11. doi: 10.1128/IAI.00734-15. PubMed PMID:
764 26553469; PubMed Central PMCID: PMC4693986.

765 33. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, Jensen KD, et al. Strain-
766 specific activation of the NF-kappaB pathway by GRA15, a novel *Toxoplasma gondii*
767 dense granule protein. *The Journal of experimental medicine*. 2011;208(1):195-212.
768 Epub 2011/01/05. doi: 10.1084/jem.20100717. PubMed PMID: 21199955; PubMed
769 Central PMCID: PMC3023140.

770 34. Braun L, Brenier-Pinchart MP, Yogavel M, Curt-Varesano A, Curt-Bertini RL,
771 Hussain T, et al. A *Toxoplasma* dense granule protein, GRA24, modulates the early
772 immune response to infection by promoting a direct and sustained host p38 MAPK
773 activation. *The Journal of experimental medicine*. 2013;210(10):2071-86. Epub
774 2013/09/18. doi: 10.1084/jem.20130103. PubMed PMID: 24043761; PubMed Central
775 PMCID: PMC3782045.

776 35. Ma JS, Sasai M, Ohshima J, Lee Y, Bando H, Takeda K, et al. Selective and
777 strain-specific NFAT4 activation by the *Toxoplasma gondii* polymorphic dense granule

778 protein GRA6. *The Journal of experimental medicine*. 2014;211(10):2013-32. Epub
779 2014/09/17. doi: 10.1084/jem.20131272. PubMed PMID: 25225460; PubMed Central
780 PMCID: PMC4172224.

781 36. Hunter CA, Sibley LD. Modulation of innate immunity by *Toxoplasma gondii*
782 virulence effectors. *Nature reviews Microbiology*. 2012;10(11):766-78. Epub
783 2012/10/17. doi: 10.1038/nrmicro2858. PubMed PMID: 23070557; PubMed Central
784 PMCID: PMC3689224.

785 37. Saraav I, Wang Q, Brown KM, Sibley LD. Secretory Microneme Proteins
786 Induce T-Cell Recall Responses in Mice Chronically Infected with *Toxoplasma gondii*.
787 *mSphere*. 2019;4(1). Epub 2019/03/01. doi: 10.1128/mSphere.00711-18. PubMed
788 PMID: 30814319; PubMed Central PMCID: PMC6393730.

789 38. Gavrilescu LC, Denkers EY. IFN-gamma overproduction and high level
790 apoptosis are associated with high but not low virulence *Toxoplasma gondii* infection. *J*
791 *Immunol*. 2001;167(2):902-9. Epub 2001/07/07. PubMed PMID: 11441097.

792 39. Mordue DG, Monroy F, La Regina M, Dinarello CA, Sibley LD. Acute
793 toxoplasmosis leads to lethal overproduction of Th1 cytokines. *J Immunol*.
794 2001;167(8):4574-84. Epub 2001/10/10. PubMed PMID: 11591786.

795 40. Takabatake N, Okamura M, Yokoyama N, Ikehara Y, Akimitsu N, Arimitsu N,
796 et al. Glycophorin A-knockout mice, which lost sialoglycoproteins from the red blood
797 cell membrane, are resistant to lethal infection of *Babesia rodhaini*. *Veterinary*
798 *parasitology*. 2007;148(2):93-101. Epub 2007/07/27. doi: 10.1016/j.vetpar.2007.06.011.
799 PubMed PMID: 17651898.

800 41. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, et al.
801 Variation in use of erythrocyte invasion pathways by *Plasmodium falciparum* mediates
802 evasion of human inhibitory antibodies. *The Journal of clinical investigation*.
803 2008;118(1):342-51. Epub 2007/12/08. doi: 10.1172/JCI32138. PubMed PMID:
804 18064303; PubMed Central PMCID: PMC2117763.

805 42. Favila MA, Geraci NS, Jayakumar A, Hickerson S, Mostrom J, Turco SJ, et al.
806 Differential Impact of LPG-and PG-Deficient *Leishmania* major Mutants on the
807 Immune Response of Human Dendritic Cells. *PLoS neglected tropical diseases*.
808 2015;9(12):e0004238. Epub 2015/12/03. doi: 10.1371/journal.pntd.0004238. PubMed
809 PMID: 26630499; PubMed Central PMCID: PMC4667916.

810 43. Nogueira PM, Assis RR, Torrecilhas AC, Saraiva EM, Pessoa NL, Campos MA,
811 et al. Lipophosphoglycans from *Leishmania amazonensis* Strains Display
812 Immunomodulatory Properties via TLR4 and Do Not Affect Sand Fly Infection. *PLoS*
813 neglected tropical diseases. 2016;10(8):e0004848. Epub 2016/08/11. doi:
814 10.1371/journal.pntd.0004848. PubMed PMID: 27508930; PubMed Central PMCID:
815 PMC4980043.

816 44. Freitas MS, Oliveira AF, da Silva TA, Fernandes FF, Goncales RA, Almeida F,
817 et al. Paracoccin Induces M1 Polarization of Macrophages via Interaction with TLR4.
818 *Frontiers in microbiology*. 2016;7:1003. Epub 2016/07/28. doi:
819 10.3389/fmicb.2016.01003. PubMed PMID: 27458431; PubMed Central PMCID:
820 PMC4932198.

821 45. Alegre-Maller AC, Mendonca FC, da Silva TA, Oliveira AF, Freitas MS, Hanna
822 ES, et al. Therapeutic administration of recombinant Paracoccin confers protection
823 against *paracoccidioides brasiliensis* infection: involvement of TLRs. *PLoS neglected*
824 *tropical diseases*. 2014;8(12):e3317. Epub 2014/12/05. doi:
825 10.1371/journal.pntd.0003317. PubMed PMID: 25474158; PubMed Central PMCID:
826 PMC4256291.

827 46. Campbell D, Mann BJ, Chadee K. A subunit vaccine candidate region of the
828 *Entamoeba histolytica* galactose-adherence lectin promotes interleukin-12 gene
829 transcription and protein production in human macrophages. *European journal of*
830 *immunology*. 2000;30(2):423-30. Epub 2000/02/12. doi: 10.1002/1521-
831 4141(200002)30:2<423::AID-IMMU423>3.0.CO;2-0. PubMed PMID: 10671197.

832 47. Murakami S, Iwaki D, Mitsuzawa H, Sano H, Takahashi H, Voelker DR, et al.
833 Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha
834 secretion in U937 cells and alveolar macrophages by direct interaction with toll-like
835 receptor 2. *The Journal of biological chemistry*. 2002;277(9):6830-7. Epub 2001/11/29.
836 doi: 10.1074/jbc.M106671200. PubMed PMID: 11724772.

837 48. Unitt J, Hornigold D. Plant lectins are novel Toll-like receptor agonists.
838 *Biochemical pharmacology*. 2011;81(11):1324-8. Epub 2011/03/23. doi:
839 10.1016/j.bcp.2011.03.010. PubMed PMID: 21420389.

840 49. Souza MA, Carvalho FC, Ruas LP, Ricci-Azevedo R, Roque-Barreira MC. The
841 immunomodulatory effect of plant lectins: a review with emphasis on ArtinM
842 properties. *Glycoconjugate journal*. 2013;30(7):641-57. Epub 2013/01/10. doi:

843 10.1007/s10719-012-9464-4. PubMed PMID: 23299509; PubMed Central PMCID:
844 PMC3769584.

845 50. Andrade WA, Souza Mdo C, Ramos-Martinez E, Nagpal K, Dutra MS, Melo
846 MB, et al. Combined action of nucleic acid-sensing Toll-like receptors and
847 TLR11/TLR12 heterodimers imparts resistance to *Toxoplasma gondii* in mice. *Cell host*
848 & *microbe*. 2013;13(1):42-53. Epub 2013/01/08. doi: 10.1016/j.chom.2012.12.003.
849 PubMed PMID: 23290966; PubMed Central PMCID: PMC3552114.

850 51. Debierre-Grockiego F, Campos MA, Azzouz N, Schmidt J, Bieker U, Resende
851 MG, et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositol derived
852 from *Toxoplasma gondii*. *J Immunol*. 2007;179(2):1129-37. Epub 2007/07/10. PubMed
853 PMID: 17617606.

854 52. Qiu J, Wang L, Zhang R, Ge K, Guo H, Liu X, et al. Identification of a TNF-
855 alpha inducer MIC3 originating from the microneme of non-cystogenic, virulent
856 *Toxoplasma gondii*. *Scientific reports*. 2016;6:39407. Epub 2016/12/22. doi:
857 10.1038/srep39407. PubMed PMID: 28000706; PubMed Central PMCID:
858 PMC5175157.

859 53. Gay G, Braun L, Brenier-Pinchart MP, Vollaire J, Josserand V, Bertini RL, et al.
860 *Toxoplasma gondii* TgIST co-opts host chromatin repressors dampening STAT1-
861 dependent gene regulation and IFN-gamma-mediated host defenses. *The Journal of*
862 *experimental medicine*. 2016;213(9):1779-98. Epub 2016/08/10. doi:
863 10.1084/jem.20160340. PubMed PMID: 27503074; PubMed Central PMCID:
864 PMC4995087.

865 54. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, et al.
866 Cutting edge: MyD88 is required for resistance to *Toxoplasma gondii* infection and
867 regulates parasite-induced IL-12 production by dendritic cells. *J Immunol*.
868 2002;168(12):5997-6001. Epub 2002/06/11. PubMed PMID: 12055206.

869 55. Plattner F, Yarovinsky F, Romero S, Didry D, Carlier MF, Sher A, et al.
870 *Toxoplasma* profilin is essential for host cell invasion and TLR11-dependent induction
871 of an interleukin-12 response. *Cell host & microbe*. 2008;3(2):77-87. Epub 2008/03/04.
872 doi: 10.1016/j.chom.2008.01.001. PubMed PMID: 18312842.

873 56. von Gunten S, Smith DF, Cummings RD, Riedel S, Miescher S, Schaub A, et al.
874 Intravenous immunoglobulin contains a broad repertoire of ant carbohydrate antibodies
875 that is not restricted to the IgG2 subclass. *The Journal of allergy and clinical*

876 immunology. 2009;123(6):1268-76 e15. Epub 2009/05/16. doi:
877 10.1016/j.jaci.2009.03.013. PubMed PMID: 19443021; PubMed Central PMCID:
878 PMC2777748.

879 57. Soldati D, Boothroyd JC. Transient transfection and expression in the obligate
880 intracellular parasite *Toxoplasma gondii*. *Science*. 1993;260(5106):349-52. Epub
881 1993/04/16. PubMed PMID: 8469986.

882 58. Kim K, Soldati D, Boothroyd JC. Gene replacement in *Toxoplasma gondii* with
883 chloramphenicol acetyltransferase as selectable marker. *Science*. 1993;262(5135):911-
884 4. Epub 1993/11/05. PubMed PMID: 8235614.

885 59. Aricescu AR, Owens RJ. Expression of recombinant glycoproteins in
886 mammalian cells: towards an integrative approach to structural biology. *Curr Opin*
887 *Struct Biol*. 2013;23(3):345-56. doi: 10.1016/j.sbi.2013.04.003. PubMed PMID:
888 23623336; PubMed Central PMCID: PMC4757734.

889 60. Mariano VS, Zorzetto-Fernandes AL, da Silva TA, Ruas LP, Nohara LL,
890 Almeida IC, et al. Recognition of TLR2 N-glycans: critical role in ArtinM
891 immunomodulatory activity. *PLoS One*. 2014;9(6):e98512. doi:
892 10.1371/journal.pone.0098512. PubMed PMID: 24892697; PubMed Central PMCID:
893 PMC4043963.


894 61. Carneiro AB, Iaciura BM, Nohara LL, Lopes CD, Veas EM, Mariano VS, et al.
895 Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but
896 counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-
897 kappaB translocation and MAPK/ERK phosphorylation. *PLoS One*. 2013;8(9):e76233.
898 doi: 10.1371/journal.pone.0076233. PubMed PMID: 24312681; PubMed Central
899 PMCID: PMC3848743.

900 62. Young L, Sung J, Stacey G, Masters JR. Detection of *Mycoplasma* in cell
901 cultures. *Nat Protoc*. 2010;5(5):929-34. doi: 10.1038/nprot.2010.43. PubMed PMID:
902 20431538.


903

904 **FIGURES**

A




B




905

Fig 1. Lectin activity of rMIC1 and rMIC4. (A) Glycoarray of the native MIC1/MIC4 subcomplex (Lac⁺) and of the recombinant forms of MIC1 and MIC4. In total, 320 oligosaccharide probes were analysed by reading their fluorescence intensities, and the 20 best recognized glycans are shown. The results were represented as previously reported [18]. **(B)** The activity and inhibition assays were performed in microplates coated with glycoproteins with or without sialic acid, fetuin (black bars), or asialofetuin (white bars), separately. After coating, wild type or mutated rMIC1 and rMIC4, pre-incubated with PBS or their corresponding sugars, were added to the wells. Later, bound proteins were detected through the addition of serum from *T. gondii*-infected mice. Data in **(B)** are expressed as mean \pm S.D. of triplicate wells and significance was calculated with ANOVA followed by Bonferroni's multiple comparisons test. *p<0.05. Data are representative of two **(B)** independent experiments. Gal: galactose; GalNAc: *N*-acetylgalactosamine; Glc: glucose; Man: mannose; Fuc: fucose; Neu5Ac: *N*-

919 acetylneuraminic acid; wt: wild type protein; mut: protein with a mutation in the
920 carbohydrate-recognition domain (CRD); ns: not significant.
921



922
923 **Fig 2. Microneme proteins stimulate cytokine production by dendritic cells and**
924 **macrophages. (A-D)** Bone marrow-derived dendritic cells (BMDCs) and **(E-H)** bone
925 marrow-derived macrophages (BMDMs) from C57BL/6 mice were stimulated with
926 rMIC1 (5 μ g/mL) and rMIC4 (5 μ g/mL) for 48 h. LPS (100 ng/mL) was used as
927 positive control. The levels of IL-12p40, TNF- α , and IL-6 were measured by ELISA.
928 For this assay, rMIC1 and rMIC4 were passed through polymyxin B column, followed
929 by incubation with polymyxin B sulphate salt media preparation that was added to the
930 culture (see Material and Methods). Data are expressed as mean \pm S.D. of triplicate wells
931 and significance was calculated with ANOVA followed by Bonferroni's multiple
932 comparisons test. * p <0.05. Data are representative of three independent experiments.
933




934

Fig 3. The IL-12 production induced by rMICs is dependent on binding to TLR2

935 **and TLR4. (A-I)** Bone marrow-derived macrophages from WT, TLR2^{-/-}, TLR4^{-/-},
936 double knockout TLR2^{-/-}/TLR4^{-/-}, TLR3^{-/-}, TLR5^{-/-}, TLR9^{-/-}, and double knockout
937 TLR11^{-/-}/TLR12^{-/-} mice, all of the C57BL/6 background, were stimulated with rMIC1
938 or rMIC4 (5 μ g/mL) for 48 h. Pam3CSK4 (P3C) (1 μ g/mL), LPS (100 ng/mL), Poly I:C
939 (10 μ g/mL), Flagellin (FLA) (1 μ g/mL) and CpG (25 μ g/mL) were used as positive
940 controls. IL-12p40 levels were measured by ELISA. **(J and K)** Transfected HEK293T
941 cells expressing TLR2 were stimulated with rMIC1 (750 nM) or rMIC4 (500 nM), and
942 rMIC1 (200 nM) or rMIC4 (160 nM) for HEK cells expressing TLR4, for 24 h. FSL-1
943 (100 ng/mL) and LPS (100 ng/mL) were used as positive controls. IL-8 levels were
944 measured by ELISA. **(L)** Western blot analysis of anti-FLAG, anti-MIC1, and anti-MIC4 in
945 various TLR and rMIC1/rMIC4 conditions.

945 measured by ELISA. **(L)** The interaction between rMICs and TLRs was evaluated by
 946 western blot. HEK293T cells transiently expressing TLR2-FLAG and TLR4-FLAG
 947 were lysed and incubated with His-rMIC1 (rMIC1^{His}) or His-rMIC4 (rMIC4^{His}). His-
 948 rMICs were subjected to Ni²⁺-affinity resin pull-down (lanes 6 to 9) and analysed for
 949 TLR2 and TLR4 binding by protein blotting with antibodies specific for FLAG-tag and
 950 then for rMIC (IgY, polyclonal). For these assays, rMIC1 and rMIC4 were passed
 951 through polymyxin B column, followed by incubation with polymyxin B sulphate salt
 952 media preparation that was added to the culture (see Material and Methods). Data in **(A-K)**
 953 are expressed as mean \pm S.D. of triplicate wells and significance was calculated with
 954 ANOVA followed by Bonferroni's multiple comparisons test. * $p<0.05$. Data are
 955 representative of three **(A-K)** and two **(L)** independent experiments.


956



957

958 **Fig 4. The cellular activation induced by rMICs via TLRs depends on**
959 **carbohydrate recognition.** **(A)** Bone marrow-derived macrophages and **(B)** bone
960 marrow-derived dendritic cells from C57BL/6 mice and **(C)** transfected HEK293T cells
961 expressing fully glycosylated TLR2 were stimulated with rMIC1 (WT) and rMIC4
962 (WT) or with their mutated forms, rMIC1-T126A/T220A and rMIC4-K469M, 5 μ g/mL
963 of each, for 48 h. LPS (100 ng/mL) and FSL-1 (100 ng/mL) were used as positive
964 controls. IL-12p40 and IL-8 levels were measured by ELISA. **(D)** HEK293T cells
965 expressing fully glycosylated TLR2 (with 4 N-glycans, WT) or glycosylation mutants
966 of TLR2 (Δ -1; Δ -4; Δ -1,2; Δ -3,4; Δ -2,4; Δ -1,2,3; Δ -1,2,3,4) were stimulated with rMIC1
967 or rMIC4. FSL-1 (100 ng/mL) was used as positive control. IL-8 levels were measured
968 by ELISA. The statistical analysis compared fully glycosylated TLR2 (WT) and TLR2
969 mutants for the N-glycosylation sites for the same stimuli. For these assays, rMIC1,
970 rMIC1-T126A/T220A, rMIC4 and rMIC4-K469M were passed through polymyxin B
971 column, followed by incubation with polymyxin B sulphate salt media preparation that
972 was added to the culture (see Material and Methods). Data are expressed as mean \pm S.D.
973 of triplicate wells and significance was calculated with ANOVA followed by
974 Bonferroni's multiple comparisons test. *p<0.05. Data are representative of three
975 independent experiments.


976



977

978 **Fig 5. The IL-12 production during *T. gondii* in vitro infection partially depends on**
 979 **MICs and their ability to recognize carbohydrates on APCs surface. (A)** Schematic
 980 representation of knockout and complementation constructs for MIC1 and MIC4 loci.
 981 The endogenous loci were disrupted using the hypoxanthine-xanthine-guanine
 982 phosphoribosyl transferase (HPT)-selectable marker and CRISPR methodology. **(B)**
 983 PCR analysis for MIC1 and MIC4 loci of gDNA from parental (WT RH- Δ ku80/ Δ hpt-
 984 GFP/Luc) and knockout (RH- Δ ku80/ Δ mic1-GFP/Luc and RH- Δ ku80/ Δ mic4-GFP/Luc)
 985 strains. **(C)** Western blot analysis of an equal loading of whole cell lysates
 986 corresponding to 3×10^6 tachyzoites (1×10^8 /mL) from WT, Δ mic1, Δ mic1::MIC1-
 987 T126A/T220A, Δ mic4 and Δ mic4::K469M parasites. The membrane was probed with


988 anti-MIC1 (IgY, 1:20,000) and anti-MIC4 (IgY, 1:8,000). **(D)** Bone marrow-derived
989 dendritic cells (BMDCs) and **(E)** Bone marrow-derived macrophages (BMDMs) from
990 C57BL/6 were infected with WT, Δmic1 , $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$, Δmic4 and
991 $\Delta\text{mic4}::\text{K469M}$ strains (MOI 3). LPS (100 ng/mL) was used as positive control. Cell-
992 culture supernatants were collected 24 hours post-infection and the IL-12p40 production
993 was analyzed by ELISA. **(F and G)** Frequency of IL-12p40⁺ BMDCs (CD11b⁺IL-
994 12p40⁺) after 20-24 hours of *in vitro* infection with WT, Δmic1 , $\Delta\text{mic1}::\text{MIC1-}$
995 T126A/T220A, Δmic4 and $\Delta\text{mic4}::\text{K469M}$ strains (MOI 1). Brefeldin A was added to
996 the culture for 8 hours. LPS (100 ng/mL) was used as positive control. **(H)**
997 Representative dot plots showing IL-12p40 staining in *T. gondii* infected or non-
998 infected (SAG1⁺ or SAG1⁻) CD11b⁺ cells after 20-24 hours of *in vitro* infection with
999 WT, Δmic1 , $\Delta\text{mic1}::\text{MIC1-T126A/T220A}$, Δmic4 and $\Delta\text{mic4}::\text{K469M}$ strains (MOI 1).
1000 Brefeldin A was added to the culture for 8 hours. LPS (100 ng/mL) was used as positive
1001 control. Data are expressed as mean \pm S.D. of triplicate wells and significance was
1002 calculated with ANOVA followed by Bonferroni's multiple comparisons test. *p<0.05.
1003 Data are representative of three **(D and E)** and two **(F-H)** independent experiments.
1004



1005
1006 **Fig 6. MIC1 lectin activity, but not MIC4, contributes to virulence in mice during**
1007 ***in vivo* infection with *T. gondii*.** CD-1 mice were infected intraperitoneally with RH
1008 engineered strains of *T. gondii* at an infectious dose of 50 tachyzoites/mouse (n=6).
1009 Mortality kinetics of mice infected with **(A)** WT, Δmic1 and $\Delta\text{mic1}::\text{MIC1-}$

1010 T126A/T220A strains or (E) WT, Δ mic4 and Δ mic4::MIC4-K469M parasites. At day 5
 1011 post-infection the sera were collected for measuring systemic (B and F) IL-12p40 and
 1012 (C and G) IFN- γ . (D, H and I) Bioluminescent detection in photons/sec/cm² shows
 1013 parasite burden 5 days post-infection. Data are expressed as mean \pm S.D. and
 1014 significance was calculated with ANOVA followed by Bonferroni's multiple
 1015 comparisons test. *p<0.05. Data are representative of three independent experiments,
 1016 with total n=16.

1017




1018

1019 **Fig 7. MIC1 wild type complemented strain restores virulence in mice during *in***
 1020 ***vivo* infection with *T. gondii*. (A)** Western blot analysis of an equal loading of whole
 1021 cell lysates corresponding to 3×10^6 tachyzoites (1×10^8 /mL) from WT, Δ mic1,
 1022 Δ mic1::MIC1-T126A/T220A and Δ mic1::MIC1 parasites. The membrane was probed

1023 with anti-MIC1 (IgY, 1:20,000), anti-HA (rabbit, 1:5,000) and anti-SAG1 (rabbit,
1024 1:10,000). **(B)** Mortality kinetics of CD-1 mice infected intraperitoneally with WT,
1025 Δ mic1, Δ mic1::MIC1-T126A/T220A and Δ mic1::MIC1 at an infectious dose of 50
1026 tachyzoites/mouse (n=5). **(C)** At day 5 post-infection the sera were collected for
1027 measuring systemic IFN- γ . **(D and E)** Bioluminescent detection in photons/sec/cm²
1028 shows parasite burden 5 days post-infection. **(F and G)** Body mass and mortality
1029 kinetics of CD-1 mice infected subcutaneously with WT, Δ mic1, Δ mic1::MIC1-
1030 T126A/T220A and Δ mic1::MIC1 using an infectious dose of 10⁴ tachyzoites/mouse.
1031 Data are expressed as mean \pm S.D. and significance were calculated with ANOVA
1032 followed by Bonferroni's multiple comparisons test. *p<0.05. Data are representative of
1033 two independent experiments, total n=10.
1034

1035 SUPPLEMENTARY INFORMATION



1036 **S1 Fig. Effect of different concentrations of rMIC1 and rMIC4 on the transfected
1037 HEK cells.** HEK293T cells expressing **(A and B)** TLR2 or **(C and D)** TLR4 were
1038 stimulated with increasing concentrations of **(A and C)** rMIC1 and **(B and D)** rMIC4
1039 for 24 h. FSL-1 (100 ng/mL) LPS (100 ng/mL) were used as positive controls. IL-8
1040 levels were measured by ELISA. Data are expressed as mean \pm S.D. of triplicate wells
1041

1042 and significance was calculated with ANOVA. *p<0.05. Data are representative of two
1043 independent experiments.